Clinical Trial Update: Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating fondaparinux to prevent thrombotic complications and graft failure in patients undergoing coronary artery bypass graft surgery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Graft Occlusion
• Coronary Artery Disease

Drugs mentioned

• Fondaparinux (fondaparinux)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Coronary Bypass Graft Failure/Occlusion | Phase 3 | Status: UNKNOWN